QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study o

Project: Research project

Description

QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination with Pembrolizumab or Nivolumab in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer who have Disease Progression Following an Initial Response to Treatment wi
StatusActive
Effective start/end date10/1/171/31/21

Funding

  • Altor BioScience Corporation

Fingerprint

Non-Small Cell Lung Carcinoma
Disease Progression
Therapeutics
pembrolizumab
ALT-803
nivolumab